Last reviewed · How we verify
Ropivacaine 0.2% Injectable Solution ESPB
At a glance
| Generic name | Ropivacaine 0.2% Injectable Solution ESPB |
|---|---|
| Also known as | erector spinae plane block |
| Sponsor | Poznan University of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Erector Spinae Plane Block for Acute Low Back Pain (NA)
- PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty (PHASE4)
- Two-level ESPB in Total Knee Arthroplasty (PHASE4)
- Erector Spinae Plane Block Vs. IPACK Block with Adductor Canal Block for Total Knee Arthroplasty (PHASE4)
- Erector Spinae vs. PENG Block for Total Hip Arthroplasty (PHASE4)
- Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Spine Surgery (PHASE4)
- ESPB vs iPACK+ACB in Total Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: